assessment of the nephroprotective properties of the erythropoietin mimetic peptide and infliximab in kidney ischemia-reperfusion injury in rats

Chronic kidney disease (ckd) or acute kidney injury (aki) causes impaired kidney function, leading to cognitive impairment, neuropathy, and cerebrovascular disease. due to kidney damage, toxins stay in the blood rather than leaving the body through the urine, and brain function is affected by kidney-brain interaction. the present study aimed to investigate the protective effects of erythropoietin mimetic peptide (phbsp) and infliximab on ischemic renal reperfusion injury. the experiment was performed on 70 white male wistar laboratory rats which received recombinant erythropoietin, phbsp, and infliximab. under anesthesia, traumatic vascular clamps were applied to the left renal pedicle for 40 min, and nephrectomy was performed on the right. functional tests and laboratory tests were performed 5 min and 24 h after the reperfusion. thereafter, 24 h after the surgery, the plasma creatinine and urea levels in the sham-operated animals were obtained at 45.9±0.8 mmol/l and 6.7±0.2 mmol/l, respectively. plasma creatinine and urea levels in the control group animals were 102.63±3.6 mmol/l and 21.80±1.29 mmol/l, respectively. the administration of phbsp and infliximab to the animals with ischemia-reperfusion kidney injury has a pronounced nephroprotective effect, as compared to erythropoietin. there was a significant decrease in blood levels of creatinine and urea, improvement of microcirculation in the kidney, normalization of glomerular filtration rate, and fractional sodium excretion. the results of the study demonstrated pointed to the prospects of phbsp and infliximab administration in ischemia-reperfusion kidney injury and justified the feasibility of further research in this field.